An article Efficacy of baloxavir marboxil on household transmission of influenza infection WOS:000576830200001 published article about SEASONAL INFLUENZA; DURATION; OSELTAMIVIR; RISK in [Umemura, Takumi; Kawamura, Takato; Saito, Masayuki; Mizuno, Takahito; Ota, Aiko; Kozaki, Koji; Yamada, Tetsuya] Tosei Gen Hosp, Dept Pharm, 160 Nishi Oiwakecho, Seto, Aichi 4898642, Japan; [Umemura, Takumi; Mutoh, Yoshikazu; Ichihara, Toshihiko] Tosei Gen Hosp, Dept Infect & Prevent, 160 Nishi Oiwakecho, Seto, Aichi 4898642, Japan; [Ikeda, Yoshiaki] Kinjo Gakuin Univ, Coll Pharm, Moriyama Ku, 2-1723 Omori, Nagoya, Aichi 4638521, Japan in 2020, Cited 20. Application In Synthesis of 3-(Trifluoromethyl)phenol. The Name is 3-(Trifluoromethyl)phenol. Through research, I have a further understanding and discovery of 98-17-9
Background Baloxavir marboxil (baloxavir) is a new anti-influenza virus agent that is comparable to oseltamivir phosphate (oseltamivir). Since the efficacy of baloxavir in preventing household transmission of influenza is not well established, we compared the secondary household influenza virus transmission rates between patients on baloxavir vs oseltamivir. Methods Between October 2018 and March 2019, we enrolled index patients (diagnosed with influenza and treated with baloxavir or oseltamivir) and household members. The secondary attack rate of household members was compared between index patients treated with baloxavir vs oseltamivir. Risk factors of household transmission were determined using multivariate logistic analyses. Results In total, 169 index patients with influenza type A were enrolled. The median age was 27.0 (interquartile range; 11-57) years. The number of index patients treated with baloxavir and oseltamivir was 49 and 120, respectively. The secondary attack rate was 9.0% (95% confidence interval [CI]: 4.6-15.6) in the baloxavir group and 13.5% (95% CI: 9.8-17.9) in the oseltamivir group. In the multivariate analysis, independent risk factors were 0-6 years of age (odds ratio [OR] 2.78, 95% CI: 1.33-5.82,p < 0.01) and not being on baloxavir treatment. (OR: 0.63, 95% CI: 0.30-1.32,p = 0.22). Conclusion The household secondary attack rate of influenza was comparable in patients treated with baloxavir vs oseltamivir. Therefore, baloxavir can be used as an alternative therapy to oseltamivir in reducing household transmission of influenza. Application In Synthesis of 3-(Trifluoromethyl)phenol. Welcome to talk about 98-17-9, If you have any questions, you can contact Umemura, T; Mutoh, Y; Kawamura, T; Saito, M; Mizuno, T; Ota, A; Kozaki, K; Yamada, T; Ikeda, Y; Ichihara, T or send Email.
Reference:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
,Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles